Cuproptosis nanoprodrug-initiated self-promoted cascade reactions for postoperative tumor therapy.

Yan, Ruiqi; Cheng, Xuan; Song, Yujing; Wang, Haiyue; Zhang, Run; Jin, Yiqi; Li, Xingguang; Chen, Yu et al. · Biomaterials · 2025

basic_science · Level V

Where this comes from

Abstract

Cancer metastasis and recurrence remain a regular cause of postoperative death in patients, implying that extra consolidation treatment strategies are needed. Here, a cuproptosis nanoprodrug, termed as Lipo@CP@DQ NPs, is developed to initiate self-promoted cascade reactions to achieve the combinational effect of cuproptosis, in situ chemotherapy, and oxidative stress amplification for effectively suppressing tumor recurrence and metastasis after postoperative treatment. Lipo@CP@DQ NPs are fabricated by loading copper peroxides (Cu<sub>2</sub>O<sub>2</sub>, CP) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-repsonsive prodrug DQ into liposomal nanoparticles. Lipo@CP@DQ NPs rapidly dissociate in the acidic tumor microenvironment to release copper ions, H<sub>2</sub>O<sub>2</sub>, and prodrug DQ. Subsequently, the excessive accumulation of Cu ions induces cuproptosis and produces highly cytotoxic hydroxyl radicals (•OH). Meanwhile, the self-supplied H<sub>2</sub>O<sub>2</sub> catalyzes the decomposition of DQ to diethyldithiocarbamate (DTC), which is chelated with self-supplied Cu ions to form the anticancer compound, Cu(DTC)<sub>2</sub>. The another decomposition product, quinone methide (QM), acts as a glutathione (GSH) scavenger for oxidative stress amplification. The synergistic effect of Lipo@CP@DQ NPs-mediated cuproptosis, in situ chemotherapy, and oxidative stress amplification effectively inhibits the growth and postoperative recurrence of triple-negative breast cancer. This work furnishes a strategy for developing cuproptosis-based nanomedicines for effective antitumor treatment after surgery.

Medical subject headings